



New Rotomolding Product Line from Equistar

2013 Annual ARM Meeting

Jim Guilfoyle

Vice President, Polyolefins Sales Americas

lyondellbasell

LyondellBasell Fast Facts

- One of the world's largest plastics, chemicals and refining companies with revenues of \$45 billion (2012)
- Global reach that addresses worldwide customer needs
- 58 manufacturing sites in 18 countries on five continents
- Sales in more than 100 countries
- Vertically integrated facilities enable conversion of crude hydrocarbons to materials for advanced applications
- Participation in 16 significant manufacturing joint ventures, 11 of which are outside of Western Europe and the United States, primarily in regions that have cost-advantaged raw materials or high growth rates



Tarragona, Spain

New Rotomolding Product Line from Equistar




Features:

- Faster rotomolding curing rates
- Curing window is expanded on the low-end, remains constant at the high-end
- Full cure at lower processing temperature (PIAT) allows for better rotopart color
- Basic physical properties remain equivalent

Benefits:

- Higher productivity
- Energy savings
- Smoother internal surface finish
- Improved rotopart color
- Processing stability maintained at the standard, longer cycle times


Expanded Rotomolding Window




New products expand the process window by shortening the time to eliminate bubbles in the rotomolded part (faster curing rate)

Faster Cure Times

Current Product



New Product



*** 0.15 inch part molded at 600°F after 14 minutes of cure time ***
Resins shown were GA-652xxx.


Smoother Inner Surface

**Current
Product**



Higher quality
rotopart aesthetics

**New
Product**



Improved surface
cleanability

Excellent
“drainability” for
tank applications

New Equistar Rotomolding Product Line

Powder Product ₁	Pellet Product	MI	Density	Certifications
MP-625962	GA-625962	5.0	0.935	UL, NSF
MP-635962	GA-635962	6.7	0.935	UL, NSF
MP-643962	GA-643962	3.6	0.9395	UL, NSF
MP-652962	GA-652962	2.0	0.942	UL, NSF
MP-672962	GA-672962	1.7	0.944	UL, NSF
MP-655962	GA-655962	5.0	0.945	UL, NSF

¹ All resins are available in powder form as Microthene or pellet form as Petrothene.

For more information please visit www.lyondellbasell.com

Disclaimer

All information (“Information”) contained herein is provided without compensation and is intended to be general in nature. You should not rely on it in making any decision. Equistar accepts no responsibility for results obtained by the application of this Information, and disclaims liability for all damages, including without limitation, direct, indirect, incidental, consequential, special, exemplary or punitive damages, alleged to have been caused by or in connection with the use of this Information. Equistar disclaims all warranties, including, but not limited to, the implied warranties of merchantability and fitness for a particular purpose, that might arise in connection with this information.

Before using a product sold by a company of the LyondellBasell family of companies, users should make their own independent determination that the product is suitable for the intended use and can be used safely and legally. SELLER MAKES NO WARRANTY; EXPRESS OR IMPLIED (INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY WARRANTY) OTHER THAN AS SEPARATELY AGREED TO BY THE PARTIES IN A CONTRACT.

This product(s) may not be used in:

- (i) any U.S. FDA Class I, Health Canada Class I, and/or European Union Class I medical devices, without prior notification to Seller for each specific product and application; or
- (ii) the manufacture of any of the following, without prior written approval by Seller for each specific product and application: U.S. FDA Class II Medical Devices; Health Canada Class II or Class III Medical Devices; European Union Class II Medical Devices; film, overwrap and/or product packaging that is considered a part or component of one of the aforementioned medical devices; packaging in direct contact with a pharmaceutical active ingredient and/or dosage form that is intended for inhalation, injection, intravenous, nasal, ophthalmic (eye), digestive, or topical (skin) administration; and tobacco related products and applications. Additionally, the product(s) may not be used in: (i) U.S. FDA Class III Medical Devices; Health Canada Class IV Medical Devices; European Class III Medical Devices; (ii) applications involving permanent implantation into the body; (iii) life-sustaining medical applications; and (iv) lead, asbestos or MTBE related applications. All references to U.S. FDA, Health Canada, and European Union regulations include another country’s equivalent regulatory classification.